Hilleman CEO On Tackling Regulatory Challenges For Vaccines
This article was originally published in Scrip
Executive Summary
Hilleman Laboratories' CEO, Dr Davinder Gill, is upbeat about the firm's tie-ups in Bangladesh for its "high-impact" cholera vaccine but underscores that it is critical to get the country's national regulatory authority (NRA) functional as quickly as possible to make such products available globally.